Table 1. Clinical and immunophenotypic features of 73 enrolled APL and AML patients.
| APL (n = 40) | AML (non-APL, n = 33) | P | |
|---|---|---|---|
| Positive Cases (%) | Positive Cases (%) | ||
| CD117 | 40 (100%) | 32 (97.0%) | 0.452 |
| MPO | 40 (100%) | 28 (84.8%) | 0.016 |
| CD13 | 40 (100%) | 21 (63.6%) | < 0.001 |
| CD33 | 40 (100%) | 29 (87.9%) | 0.038 |
| CD64 | 40 (100%) | 3 (9.1%) | < 0.001 |
| CD11c | 6 (15%) | 21 (63.6%) | < 0.001 |
| CD15 | 11 (27.5%) | 8 (24.2%) | 0.795 |
| CD56 | 3 (7.5%) | 7 (21.2%) | 0.169 |
| CD123 | 29 (72.5%) | 23 (69.7%) | 0.801 |
| CD38 | 28 (70%) | 25 (75.8%) | 0.610 |
| CD34 | 3 (7.5%) | 0 (0%) | 0.247 |
| HLA-DR | 2 (5%) | 0 (0%) | 0.498 |
| CD2 | 3 (7.5%) | 0 (0%) | 0.247 |
| CD14 | 0 (0%) | 1 (3.03%) | 0.452 |
| CD11b | 0 (0%) | 4 (12.1%) | 0.038 |
| CD10 | 0 (0%) | 0 (0%) | - |
| cCD79α | 0 (0%) | 0 (0%) | - |
| cCD3 | 0 (0%) | 0 (0%) | - |
| CD4 | 0 (0%) | 0 (0%) | - |
| CD16 | 0 (0%) | 0 (0%) | - |
| CD7 | 0 (0%) | 0 (0%) | - |
| CD19 | 0 (0%) | 0 (0%) | - |
Note: Seventy-three patients with APL-like immunophenotypes were selected from 323 AML patients in Changhai hospital between September 2011 and December 2014 in which only 54.8% were finally confirmed as APL.